OGT - Key Persons
Job Titles:
- Chief Executive Officer
- Member of the Board
- Member of the Executive Team
Job Titles:
- Member of the Executive Team
- Executive Vice President, Strategic Business Development
Dr Emma Shipstone joined OGT in April 2014 to lead the marketing team, and moved into her current role as Executive Vice President for Strategic Business Development in May 2021.
Emma is responsible for the identification, evaluation and management of external partnerships and strategic opportunities to help deliver growth for OGT.
Emma has over 20 years' experience in the life sciences and genomics fields and her experience spans both R&D and Commercial roles from her time at GE Healthcare, formerly Amersham Biosciences.
Prior to joining OGT, she spent 6 years at Affymetrix where she held the position of Senior Director of Marketing leading the European marketing and inside sales teams.
Job Titles:
- Executive Vice President, Research and Development
- Member of the Executive Team
- Executive Vice President of R & D
Dr Graham Speight joined OGT in January 2007 to lead the molecular biology research and development (R&D) team. Since then, he oversaw the development of the array services and genomic biomarker businesses. More recently he has been responsible for developing the oncology NGS product portfolio.
Dr Speight was appointed as Executive Vice President of R&D in April 2018 and is an experienced research director, bringing a wealth of knowledge in molecular biology/genetics and product development.
Prior to joining OGT, Dr Speight obtained a PhD in neuropsychiatric genetics, following which he gained experience of target and drug discovery in the pharmaceutical industry. During his career he has also gained broad experience in oncology research.
Job Titles:
- Member of the Board
- Non - Executive Director
Dr Kenji Tsujimoto joined OGT as a Non-Executive Director in 2017.
He is also an Executive Vice President of Technology Strategy in Sysmex Corporation, a global leading in vitro diagnostics company.
Previously as an Executive Vice President of Business Strategy in Sysmex, Kenji spent 5 years leading M&A and other share purchase transactions.
Prior to joining Sysmex, Kenji held a range of roles such as strategic planning, R&D, investment and marketing with 13 years' experience in pharmaceutical and biotech spaces.
Job Titles:
- Member of the Board
- Non - Executive Director
- CEO Led the Transformation from a Licensing
Dr Mike Evans joined OGT in March 2005 and as CEO led the transformation from a licensing-led business model to a highly successful genomic products business - delivering innovative genetics research solutions to advance molecular medicine.
In 2018 Mike became a Non-Executive Director on the OGT board.
Before joining OGT, Mike held a number of senior positions at GE Healthcare/Amersham Biosciences, including Executive Vice President, Marketing and Strategy and Executive Vice President, Corporate Development. In 2000 Mike joined Ascot plc as Managing Director, Fine Chemicals, responsible for two businesses within the Ascot plc group and was a member of Ascot's Executive Committee.
Mike has also held several non-executive directorships and was chairman of TAP Biosystems Group plc until its sale to Sartorius Stedim Biotech. Mike holds a BA, MA and DPhil from the University of Oxford.
Job Titles:
- Member of the Executive Team
- Executive Vice President, Commercial Operations
Gareth Thomson joined OGT in 2009 and is responsible for OGT's commercial operations.
He brings more than 24 years' commercial experience working in the Life Science market with a specialist focus in clinical genomics, microarrays and next generation sequencing.
Most recently, he led OGT's global sales and support functions and has previously held a number of sales and marketing roles at leading companies such as GE Healthcare and Affymetrix.
Job Titles:
- Chief Financial Officer
- Member of the Board
- Member of the Executive Team
- Chief Financial Officer in September 2018. Greg Has Extensive Experience in Finance With 20 Years of History Working across a Broad Range of Areas
Greg Williams joined OGT as Chief Financial Officer in September 2018. Greg has extensive experience in finance with 20 years of history working across a broad range of areas.
Greg has previously held roles including Chief Financial Officer of a 74 bed private hospital in Chelsea, London as well as Chief Financial Officer of the Primary Care division of HCA International; a large private hospital group where he worked for over 10 years.
Greg has been successful at driving financial strategy in a high growth environment and is a qualified Chartered Accountant. He has also previously worked at Grant Thornton in Central London.
Job Titles:
- Member of the Board
- Non - Executive Director
- President and CEO of Riken Genesis Corporation
Naoto Kondo is president and CEO of Riken Genesis corporation, a genomics, personalised medicine, and pharmaceutical services laboratory headquartered in Tokyo.
Prior to this Naoto set up Illumina KK in Japan. His early career was in the pharmaceutical and medical devices industry initially as an R&D researcher then moving into marketing and business management.
Naoto holds a Ph.D from Nagoya University.
Job Titles:
- Executive Vice President, Operations
- Member of the Executive Team
Sharon Lloyd joined OGT in November 2022 to lead OGT Operations, responsible for Production, Packaging, Shipping, Customer Services, EHS and Facilities, ensuring the development and implementation of efficient operations and cost-effective systems to meet current and future needs of the organisation.
Sharon has 30 years' experience in life sciences and pharmaceutical operations spanning Manufacturing, R&D, Facilities, Engineering, Marketing, Programme & Project Management, and Business Excellence roles from her time at GE Healthcare, Hologic, Becton Dickinson, and BPL.
Prior to joining OGT, she spent 3 years at BPL where she held the position of Director of Business Excellence with responsibility for Training, Operational Excellence, PMO, and EH&S.
Job Titles:
- Member of the Executive Team
- Executive Vice President of Regulatory
- Executive Vice President, Regulatory, Medical and Quality Affairs
Steve Chatters joined OGT in September 2015, firstly as Product Manager for the CytoCell® FISH probe range, then leading the Medical Affairs team in which he oversaw the successful FDA de novo 510(k) clearance of OGT CytoCell AML/MDS probes.
Steve was appointed Executive Vice President of Regulatory, Medical and Quality Affairs in July 2020 with responsibility for delivering OGT's quality systems, regulatory processes and analytical testing.
Before joining OGT, Steve was Principal Clinical Scientist of the oncology cytogenetic service at Great Ormond Street Hospital in London UK and has over 20 years' experience in specialist cancer diagnostic laboratories.
Job Titles:
- Company Secretary
- Financial Controller
- Member of the Executive Team
Tony Lenhardt joined the finance group in May 2005, bringing an established track record in financial management from working for a diverse range of companies where he held a number of senior roles.
Tony was appointed Company Secretary in May 2006 and heads the HR and IT departments.